Showing 1191-1200 of 21420 results for "".
- Induction Therapies Launches Recovery Serum for At-Home Skincare Supporthttps://reachmd.com/news/induction-therapies-launches-recovery-serum-for-at-home-skincare-support/2487505/Induction Therapies has introduced YouthXO + PDRN, a new recovery and renewal serum designed to support skin health between professional aesthetic treatments and as part of a daily skincare regimen. According to the company, the serum combines plant exosomes, vegan polydeoxyribonucleotide
- Early Inertial Training After ACL Reconstructionhttps://reachmd.com/news/early-inertial-training-after-acl-reconstruction/2487498/Key Takeaways Added inertial training was associated with greater restoration of morphological symmetry and interlimb symmetry under inertial loading. Isokinetic knee strength and dynamic balance were comparable between groups at 12 weeks. Onl
- Ensitrelvir Did Not Improve Recovery in Hospitalized Adults With Covid-19https://reachmd.com/news/ensitrelvir-did-not-improve-recovery-in-hospitalized-adults-with-covid-19/2487487/Key Takeaways Ensitrelvir plus standard of care was not associated with a significant improvement in clinical recovery through day 60 compared with placebo plus standard of care. Detectable plasma viral antigen at day 5 was lower with ensitrelvir, but
- Early SGLT2 Inhibitor Use in Takotsubo Syndromehttps://reachmd.com/news/early-sglt2-inhibitor-use-in-takotsubo-syndrome/2487495/Key Takeaways Early SGLT2 inhibitor use was associated with lower all-cause mortality in the propensity-matched analysis. No significant associations were reported for heart failure hospitalization, cardiogenic shock, cardiac arrest, or major adverse c
- Higher Intraoperative Blood Pressure Targets in Noncardiac Surgeryhttps://reachmd.com/news/higher-intraoperative-blood-pressure-targets-in-noncardiac-surgery/2487499/Key Takeaways Higher targets were not associated with less acute kidney injury or acute myocardial injury, and trial sequential analysis supported those null findings. No significant effect was observed for in-hospital or 30-day mortality, while eviden
- Cagrilintide-Semaglutide Added to Basal Insulin in REIMAGINE 3https://reachmd.com/news/cagrilintide-semaglutide-added-to-basal-insulin-in-reimagine-3/2487497/Key Takeaways Once-weekly cagrilintide-semaglutide added to basal insulin was associated with larger week-40 HbA1c reductions than placebo. Body weight decreased by 10% to 12% across the active-dose groups. Adverse events were mostly mild or m
- FDA Expands Dupilumab CSU Indication to Children as Young as 2 Yearshttps://reachmd.com/news/dupilumab-approval-expanded-to-include-children-as-young-as-2-years-with-csu/2487479/The US Food and Drug Administration (FDA) has expanded the indication for dupilumab (Dupixent; Sanofi and Regeneron) to include pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The label expansion, according
- Picankibart Phase III Trial Reports Week 16 Clearance and Week 52 Durabilityhttps://reachmd.com/news/picankibart-phase-iii-clearance-durability/2487475/Key Takeaways At week 16, both co-primary endpoints favored picankibart over placebo in Chinese adults with moderate to severe plaque psoriasis. All key secondary endpoints also improved, and efficacy was maintained through week 52 with both 100 mg and
- mRNA Seasonal Influenza Vaccine Shows Superiority in Adultshttps://reachmd.com/news/mrna-seasonal-flu-vaccine-adults/2487477/Key Takeaways Investigators observed a relative vaccine efficacy of 26.6% with mRNA-1010, and the authors concluded superiority versus standard-dose licensed vaccines for the prespecified endpoint. Cases of RT-PCR–confirmed, protocol-defined influenza-
- FDA Approves Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel for Midface Augmentationhttps://reachmd.com/news/fda-approves-obagi-saypha-chiq-injectable-hyaluronic-acid-gel-for-midface-augmentation/2487470/Waldencast plc announced that the US Food and Drug Administration (FDA) has approved Obagi® saypha® ChIQ™ injectable hyaluronic acid (HA) gel, expanding the Obagi Medical injectable portfolio and strengthening the company’s position within the medical aesthetics market. According to the co